Poziotinib

Drug Profile

Poziotinib

Alternative Names: HM-78136B; NOV120101

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Chonnam National University Hospital; Chungnam National University; Hanmi Pharmaceutical; Konkuk University Medical Center; Korean Association for the Study of Targeted Therapys; Kosin University Gospel Hospital; Kyungpook National University Medical School; Spectrum Pharmaceuticals; Yonsei University Health System
  • Class Anilinouracils; Antineoplastics; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer
  • Clinical Phase Unknown Colorectal cancer

Most Recent Events

  • 08 Dec 2016 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 17th World Conference on Lung Cancer (WCLC-2016)
  • 08 Dec 2016 Spectrum Pharmaceuticals plans a investigator-sponsored phase II trial for Non-small cell lung cancer in USA ,
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top